Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Exicure Inc (XCUR)

Exicure Inc (XCUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant GlobeNewswire - Thu Feb 5, 6:00AM CST

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication...

XCUR : 4.03 (-5.40%)
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings GlobeNewswire - Wed Jan 21, 6:00AM CST

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it...

XCUR : 4.03 (-5.40%)
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting GlobeNewswire - Mon Dec 8, 2025

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive...

XCUR : 4.03 (-5.40%)
Exicure, Inc. Reports Third Quarter 2025 Financial Results GlobeNewswire - Fri Nov 7, 2025

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. ...

XCUR : 4.03 (-5.40%)
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting GlobeNewswire - Mon Nov 3, 2025

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results...

XCUR : 4.03 (-5.40%)
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights Business Wire - Wed Oct 22, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

XCUR : 4.03 (-5.40%)
Exicure Highlights Recent Achievements and Near-term Strategic Priorities GlobeNewswire - Mon Oct 6, 2025

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug...

XCUR : 4.03 (-5.40%)
Exicure, Inc. Reports Second Quarter 2025 Financial Results Business Wire - Fri Aug 8, 2025

Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results...

XCUR : 4.03 (-5.40%)
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements Business Wire - Mon Aug 4, 2025

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the...

XCUR : 4.03 (-5.40%)
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant Business Wire - Fri Aug 1, 2025

Topline results expected H2 2025

XCUR : 4.03 (-5.40%)

Barchart Exclusives

These 3 Dividend Stocks Combine Income, Momentum, and Upside Barchart - Fri Feb 6, 6:00PM CST
Three dividend stocks with strong buy ratings, solid income today, and upside potential in 2026 based on Barchart strength and analyst consensus. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot